1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Natural History Studies Grant Program is sponsored by FDA. The Natural History Studies Grants Program supports efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs.
These studies can help at every stage of product development, such as identifying the patient population, identifying or developing clinical outcome assessments and biomarkers, and when appropriate, serving as external controls.
Get alerted about grants like this
Get emailed when new opportunities from “FDA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: This program is intended to fund well-designed, protocol-driven natural history studies with high quality and interpretable data elements that address knowledge gaps, support clinical trials and advance rare disease medical product development. Confirm the full requirements in the official notice before applying.
Natural History Studies Grant Program is funded by FDA. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
IFDA Philadelphia Scholarship is a scholarship from the IFDA Educational Foundation, supported by the IFDA Philadelphia Chapter, that awards $2,500 to a full-time current undergraduate student enrolled in an interior design or related program. The scholarship is administered by the IFDA Educational Foundation, a 501(c)(3) nonprofit dedicated to supporting the home furnishings and design community through educational funding. Eligible applicants are full-time undergraduate students supported by the Philadelphia Chapter. The deadline for the current cycle was March 31, 2026.
Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers is sponsored by FDA Oncology Center of Excellence (OCE). Funds research to develop approaches to support drug development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers, especially those with high unmet medical need and little economic incentive for commercial entities to conduct research.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.